Turning the Tide Against Carbapenem-resistant Acinetobacter baumannii : Advancing Care With Sulbactam–Durlobactam
Abstract
Acinetobacter baumannii is a Gram-negative opportunistic pathogen that presents significant challenges in healthcare settings, particularly in intensive care units (ICUs) and long-term acute care hospitals (LTACHs). It is among the leading nosocomial pathogens associated with ventilator-associated pneumonia (VAP), ranking as the 10th most frequently reported pathogen in ICUs, where it accounted for 3.2% of cases. In LTACHs, it plays an even more prominent role, ranking 4th and contributing to 6.6% of VAP cases [1]. The World Health Organization (WHO) has designated carbapenem-resistant A. baumannii (CRAB) as a critical priority pathogen due to its extensive antimicrobial resistance, the limited treatment options, and global health impact [2–4]. This paper explores the clinical and epidemiological aspects of A. baumannii, the challenges posed by existing therapies, and the emergence of sulbactam–durlobactam (SUL/DUR) as a promising therapeutic option. The global epidemiology of A. baumannii reflects its position as a leading cause of nosocomial infections and a critical public health challenge due to its rapid acquisition of multidrug resistance (MDR). CRAB is particularly concerning, with its prevalence intensifying in several regions globally. The Mediterranean region remains a significant hotspot, where over 90% of clinical isolates demonstrate carbapenem resistance [5]. Indeed, similar data are reported from various parts of the world as can be seen in Figure 1. Global…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 196 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.